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Introduction
Gene expression proﬁ  ling of peripheral blood or aﬀ  ected 
tissues in patients with autoimmune diseases has 
revealed important insights into the molecular pathways 
underlying autoimmunity [1]. Several groups have used 
gene expression proﬁ  ling in an attempt to uncover clues 
to the pathogenesis of dermatomyositis (DM) (Table 1). 
Th  e most prominent and consistent ﬁ   nding of these 
studies has been the presence of a gene signature charac-
teristic of type I interferon (IFN) pathway activation, 
discovered ﬁ  rst in DM muscle tissue and later identiﬁ  ed 
in peripheral blood cells.
Th  e identiﬁ  cation of IFN occurred over 50 years ago 
when IFN was observed to be produced in response to 
viral illnesses. More recently, type I IFNs have been 
identi ﬁ   ed as an important mediator in autoimmune 
diseases including juvenile dermatomyositis (JDM) and 
adult dermatomyositis (ADM). Th  ere are at least three 
classes of IFNs, including what are referred to as type I 
IFNs, which in humans include 13 subtypes of IFNα, 
IFNβ, IFNω, IFNε, and IFNκ. All of the type I IFNs are 
thought to signal through the same receptor, type I IFN 
receptor. Other IFNs have been seen in autoimmune 
disorders, including DM, such as type II IFN (IFNγ) that 
is mainly produced by natural killer cells and activated T 
cells (T-helper type 1 cells), and type III IFNs that are a 
newly discovered class consisting of three members – 
IFNγ1, IFNγ2, and IFNγ3 – which have overlapping 
activities with type I IFNs but signal through a distinct 
receptor [2].
Interferon-inducible gene expression in 
dermatomyositis muscle
Two microarray studies in limited numbers of DM 
patients provided the earliest evidence that type I IFN-
inducible genes are upregulated in DM muscle tissue. 
Among the genetic risk factors for DM are HLA class II 
alleles. Over 85% of JDM patients are positive for 
DQA1*0501, as compared with only 25% of healthy con-
trols [3]. In 2002 Tezak and colleagues described Aﬀ  ymetrix 
gene expression proﬁ  ling of muscle biopsy tissue from 
four female Caucasian JDM patients, all of whom were 
DQA1*0501-positive [4]. Of the genes identiﬁ  ed  as 
upregulated in JDM when compared with normal age-
matched controls or children with Duchenne muscular 
dystrophy, many were known to be transcriptionally 
induced by type I IFN. Th  e degree of upregulation was 
quite striking, with the average fold-change in expression 
for some IFN-inducible genes approaching 100× in the 
JDM patients versus normal controls.
Another study published by Pachman and colleagues 
evaluated the inﬂ   uence of the duration of chronic 
inﬂ  ammation on gene expression in skeletal JDM muscle 
[5]. Biopsies of 16 female JDM patients who were thought 
to have active disease for ≥2 months were compared with 
those of three female JDM patients who were thought to 
have active disease for <2  months using Aﬀ  ymetrix 
U133A chips. Th   e patients were untreated at the time of 
biopsy and four matched controls were included. Many 
of the overexpressed genes were IFNα/β inducible and 
similarly found in Tezak and colleagues’ study. Results 
were conﬁ  rmed by array proﬁ  ling of biopsies from eight 
additional untreated JDM patients. Th   ere were no signi-
ﬁ  cant diﬀ  erences in type I IFN-induced gene expression 
between the long and short disease duration patients, 
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© 2011 BioMed Central Ltdhowever, suggesting that overexpression of IFN-induced 
genes was independent of the duration of the inﬂ  am-
matory response.
In 2004 another group reported on cDNA microarray 
proﬁ   ling of muscle biopsies from 10 adult idiopathic 
inﬂ  ammatory myositis (IIM) patients (four ADM and six 
polymyositis (PM)) with active, mostly untreated, disease 
[6]. Of 25 genes found to be upregulated in IIM versus 
normal controls (n = 5), several were known to be IFN 
inducible. While the number of samples in each IIM 
subtype was too small to identify genes diﬀ  erentially 
expressed between ADM and PM, the upregulation of 
IFN-inducible genes was apparent in three out of four 
ADM patients and in two out of six PM patients.
A larger cohort of IIM patients was studied in 2005, 
when global gene expression proﬁ  les were obtained from 
skeletal muscle biopsies of 54 patients (14 ADM, 20 
inclusion body myositis (IBM), six PM, and 14 other) and 
10 normal controls using Aﬀ  ymetrix U133A GeneChips 
[7]. Of the 14 most highly upregulated genes in ADM, 12 
were type I IFN inducible. Hierarchical clustering 
analysis of the DM patients and normal controls revealed 
a striking cluster of IFN-regulated genes. In general, the 
IFN-inducible genes were found at higher levels in ADM 
as compared with other IIM patients. Th  e authors also 
found a relative abundance of type I IFN-producing 
plasmacytoid dendritic cells in muscle sections from 10 
out of 14 patients with ADM.
In 2010 the Greenberg group again applied Aﬀ  ymetrix 
U133A chips to muscle biopsies from another large 
cohort of 76 IIM patients (14 ADM, 24 IBM and 38 PM/
other), along with 26 patients with noninﬂ  ammatory 
myopathies and 11 individuals without neuromuscular 
disease [8]. Th   e IFN signature genes were highly 
upregulated in the ADM muscle, particularly in those 
patients with perifascicular atrophy, a common feature of 
DM in which small muscle ﬁ  bers are found around the 
edges of fascicles. Importantly, the authors demonstrated 
that the IFN signature in ADM muscle closely mimicked 
the pattern generated by in vitro stimulation of human 
peripheral blood mononuclear cells with type I IFNs, but 
not by other cytokines (IFNγ, TNFα, granulocyte–
macrophage colony-stimulating factor, IL-10, IL-1β, and 
IL-13). Th  ey also showed that human skeletal muscle 
cells cultured with type I IFNs showed upregulation of 
many of the same transcripts that are elevated in ADM 
patient muscle.
In addition to reporting on the full IFN signature, this 
study speciﬁ   cally examined the ubiquitin-like modiﬁ  er 
IFN-stimulated gene 15 (ISG15) and its enzymatic 
pathway, which includes three conjugating enzymes 
(Ube1L, Ube2L6, and HERC5) and a deconjugating 
enzyme (USP18). Th  e authors previously demonstrated 
that ISG15 was the most overexpressed gene in DM 
muscle compared with both normal muscle as well as 
muscle from patients with other types of IIM [8]. Here 
they reported that  transcript levels for ISG15 and the 
related enzymes were elevated in DM patients with 
perifascicular atrophy as compared with DM patients 
without perifascicular atrophy, and in DM compared 
with other muscle diseases. Using immunohistochemistry 
and immunoﬂ  uorescence, they demonstrated that ISG15 
protein is localized to perifascicular myoﬁ  bers  and 
capillaries in DM muscle. MxA, a putative ISG15-
conjugated protein, was similarly localized.
An important question not directly addressed by the 
above studies is the potential eﬀ  ect of treatment on gene 
expression patterns. Raju and Dalakas examined 
Aﬀ   ymetrix U133A gene expression proﬁ   les in muscle 
from three ADM patients before and after treatment with 
intravenous immunoglobulin [9]. All three patients 
showed major clinical improvement following treatment. 
Table 1. Summary of studies demonstrating a type I interferon signature in dermatomyositis muscle or blood 
  Array format (approximate
Reference  number of genes) or other platform  Tissue  Sample size
Tezak and colleagues [4]  Aff  ymetrix HuFL (5,600)  Muscle  4 JDM
Zhou and colleagues [6]  cDNA (4,000)  Muscle  6 PM, 4 DM
Greenberg and colleagues [7]  Aff  ymetrix U133A (16,000)  Muscle  13 DM, 6 PM, 20 IBM
Raju and Dalakas [9]  Aff  ymetrix U133A (16,000)  Muscle  3 DM, 4 IBM
Chen and colleagues [5]  Aff  ymetrix U133A (16,000)  Muscle  31 JDM
Salajegheh and colleagues [8]  Aff  ymetrix U133A (16,000)  Muscle  14 DM, 24 IBM, 38 PM/other
O’Connor and colleagues [16]  Quantitative real-time RT-PCR  Blood  14 JDM
Walsh and colleagues [24]  Aff  ymetrix U133A 2.0+ (38,500)  Blood  12 DM, 11 PM, 13 IBM
Baechler and colleagues [23]  Aff  ymetrix U133A 2.0+ (38,500)  Blood  10 DM, 2 JDM
Bilgic and colleagues [25]  Quantitative real-time RT-PCR  Blood  37 DM, 19 JDM
Liao and colleagues [26]  Aff  ymetrix U133A 2.0+ (38,500)  Blood  24 DM, 12 PM, 15 IBM, 7 othera
aIncludes some previously published data. DM, dermatomyositis; IBM, inclusion body myositis; JDM, juvenile dermatomyositis; PM, polymyositis.
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among those that exhibited signiﬁ  cantly  altered 
expression following treatment, the IFN-inducible gene 
STAT1 was upregulated in the pretreatment DM and 
IBM muscle biopsies compared with two normal controls.
Interferon-inducible protein expression in 
dermatomyositis muscle and skin
In conjunction with the IFN gene expression, proteins 
known to be type I IFN induced have been noted to be 
overexpressed in the two most common tissues aﬀ  ected 
by JDM and ADM – the muscle and skin.
Th  e exact mechanisms of pathogenesis of JDM and 
ADM by type I IFNs is not clearly known. Healthy 
myoﬁ  bers usually express very little MHC class I, whereas 
upregulation of MHC class I expression is seen in aﬀ  ected 
tissue from patients with IIM. Type I IFNs are suggested 
promoters of MHC class I expression in JDM and ADM 
muscle tissue; however, IFNα and IFNβ have not been 
consistently detected in tissue or peripheral blood. Th  e 
eﬀ  ects of type I IFNs, however, may contribute to the 
pathogenesis of JDM and ADM by leading to increased 
production of proinﬂ   ammatory cytokines and chemo-
kines. Increased expression of type I IFN-inducible α-
type CXC chemokines (MIG/CXCL9, IP10/CXCL10 and 
I-TAC/CXCL11) is reported along with CXCR3-bearing 
lymphocytes to sites of inﬂ  ammation in muscle [10,11] 
and skin [12,13]. In skin tissue, IFN has been shown to 
induce keratinocyte production of chemokine ligands 
such as CXCL9, CXCL10 and CXCL11, which are critical 
chemokines directing the recruitment of CXCR3-bearing 
T lymphocytes.
Evidence for type I IFN-related protein expression in 
DM was ﬁ  rst provided when the expression of the MxA 
protein, a speciﬁ  c marker for type I IFN activation, was 
detected in aﬀ   ected ADM skin [14] and muscle [7]. 
Immunohistochemical protein staining in ADM muscle 
correlated MxA staining with the microarray-measured 
transcript levels, which are pronounced in the ADM 
samples but not those of other inﬂ  ammatory  muscle 
disease samples (IBM, PM, dystrophies and necrotizing 
myositis). Th  e staining of MxA protein, when present, 
was preferentially in the perifascicular area of the muscle 
[8]. Along with MxA, Greenberg has shown ISG15 
protein and ISG15-conjugated proteins in the peri-
fascicular atrophic muscle of seven ADM patients, but 
these proteins were not seen in four ADM patients who 
did not have perifascicular atrophy or in IBM or PM 
subjects [8]. Th  ese ﬁ  ndings suggest that ADM may be 
associated with upregulation of the ISG15 pathway in 
conjunction with an escalation of MxA protein.
Elevated levels of MxA protein are not only evident in 
the perifascicular atrophic muscle but in skin biopsies 
from ADM and JDM subjects. Skin biopsies from 11 
ADM subjects stained for MxA protein in both the 
epidermis and in the inﬂ  ammatory inﬁ  ltrates when the 
samples were compared with healthy control biopsies 
[13]. To identify the source of the potential type I IFN-
expressing inﬂ   ammatory cells, Wenzel and colleagues 
stained for the presence of plasmacytoid dendritic cells 
(pDCs). Th  ey identiﬁ   ed CD123-positive pDCs in the 
skin, consistent with what has been previously reported 
in the muscle tissue in both ADM and JDM [11]. 
Similarly, Shrestha and colleagues found increased MxA 
staining and more mature pDCs in skin from patients 
with juvenile DM compared with control tissues [15]. 
Type I IFNs have been shown to promote traﬃ   cking of 
immune cells by stimulating the production of CXCR3 
ligands, including MIG/CXCL9, IP10/CXCL10 and I-
TAC/CXCL11, which were seen in the ADM skin tissue, 
alongside CXCR3-positive lymphocytes. In vitro experi-
ments using IFNα showed induction of IP10 in keratino-
cyte cultures [14], suggesting a direct relationship 
between IFN and cell traﬃ   cking  response.  Aﬀ  ected 
muscle and skin in DM share a common pathogenic 
mecha  nism involving type I IFN mediation, even though 
upregulation of MxA mRNA expression in peripheral 
blood mononuclear cells correlated with muscle disease 
activity scores but not with skin disease scores in JDM 
[16].
Chemokines and cytokines are known to be up  regu-
lated in tissue from DM subjects and are hypothesized to 
regulate MHC class I upregulation, and recruitment of 
inﬂ   ammatory lymphocytes – speciﬁ   cally T cells [17]. 
Monocyte chemo  attractant protein-1 (MCP-1/CCL2) 
and the macrophage inﬂ  ammatory protein-1 (MIP-1α/
CCL3 and MIP-1β/CCL4) have been studied extensively 
in IIM muscle tissues and found to have a consistently 
higher expression in ADM while JDM has not been 
studied [18-21].
Liprandi identiﬁ   ed MCP-1 mRNA in all adult IIM 
groups (eight ADM, ﬁ   ve PM and four IBM) with the 
highest expression being seen in muscle tissues from 
eight cases of ADM. In situ hybridization showed MCP-1 
mRNA accumulation preferentially in perivascular mono-
nuclear cells [21]. Further exploration of both MCP-1 
and MIP-1α demonstrated immunohistochemical stain-
ing and PCR ampliﬁ  cation in seven DM patients as well 
as other forms of inﬂ  ammatory myositis (six PM and ﬁ  ve 
IBM) [19]. MCP-1 and MIP-1 were always located in, or 
in close proximity to, inﬂ   ammatory cells inﬁ  ltrating 
muscle tissue. MIP-1β staining was seen in all blood 
vessels including capillaries in six ADM muscle samples 
even in sites away from the inﬂ  ammatory inﬁ  ltrate, which 
raises a question regarding the role of MIP-1β in the early 
prediction of disease onset [18].
Diﬀ  usely stained endothelial expression of MCP-1 was 
also seen in the perifascicular and perimysial in six ADM 
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Th  is suggests a role for MCP-1 in the complement-
mediated response in ADM, since complement deposi-
tion is reported in ADM and JDM in the endothelial cells. 
Further identiﬁ  cation of the chemokine receptors, which 
are the primary receptor for MCP-1, were identiﬁ  ed in 
six ADM muscle biopsies with an increase endothelial 
expression of CCR2A and an increase of CCR2B on the 
inﬂ  ammatory cells. Th  ese  ﬁ  ndings were observed in all of 
the myositis subgroups studied (ADM, PM and IBM) 
[10].
Not only are type I IFNs associated with increased 
levels of MCP-1 but in vitro data support the suggestion 
that IFNγ (type II IFN) may also be involved in muscle 
pathophysiology. Human myoblasts stimulated with 
IFNγ and/or TNFβ demonstrate an increase of MCP-1 
expression in the myoblast culture supernatants (IFNγ 
2,510 pg/ml or TNFα 2,915 pg/ml or both 3,670 pg/ml), 
which was not found in supernatants from untreated 
myoblasts. Along with MCP-1 the cytokine IL-6 was 
elevated in the supernatants, also induced by treatment 
with IFNγ or TNFβ where the maximum expression was 
obtained with the combination of cytokines (IFNγ 
5,918 pg/ml or TNFα 16,811 pg/ml or both 27,040 pg/ml) 
[22]. Th   is suggests not only that type I IFNs are associated 
with an increase of IL-6 and MCP-1, but that other 
cytokines – even those involved in the T-helper type 1 
(IFNγ) and T-helper type 17 cytokine pathway – may be 
involved in inﬂ  ammatory muscle pathology.
Th  e local IFN milieu supports the activation and 
migration of cells involved in the adaptive immune res-
ponse. Th   e observation that IFN can cause cell migration 
and maturation and can manipulate tissue chemokine 
and cytokine production, which leads to muscle, keratino-
cyte, and endothelial cell injury, supports the idea that 
type I IFNs are pivotal in the development of DM.
Interferon gene signature in dermatomyositis 
blood: from a single transcript to a global 
signature
Th  e ﬁ   nding of an IFN gene signature in DM muscle 
revealed potential disease mechanisms and candidate 
biomarkers for DM. Several groups next began interro-
gating gene expression in peripheral blood cells in the 
hope of identifying disease biomarkers that could be 
measured in a less-invasive and less-expensive fashion. 
Th  e  ﬁ  rst suggestion that type I IFN-inducible transcripts 
were elevated in DM blood cells came in 2006, when 
O’Connor and colleagues used quantitative real-time RT-
PCR to demonstrate that MxA mRNA levels were signiﬁ  -
cantly elevated in peripheral blood mononuclear cells 
from 14 JDM patients as compared with 24 healthy 
pediatric controls [16]. Th   e evidence also suggested that 
MxA expression in blood was correlated with muscle, but 
not skin, disease activity scores. In 11 patients with 
follow-up samples available, the change in MxA 
expression was signiﬁ  cantly correlated with the change in 
muscle disease activity scores, but not skin disease 
activity scores, at 1-year follow-up.
Th  e following year, we reported the results of gene 
expression proﬁ  ling in peripheral blood mononuclear cells 
of 10 ADM and two JDM patients [23]. Despite previous 
reports of the IFN signature observed in DM muscle, we 
did not ﬁ  nd strong representation of IFN-regulated genes 
among those most diﬀ  erentially ex  pressed between DM 
and healthy controls. In a hier  archical clustering analysis 
of 315 genes previously identi  ﬁ  ed as type I IFN regulated, 
however, we found a striking cluster of IFN-inducible 
genes that were up  regulated in 10 of the 12 DM patients. 
Th  e data also suggested that the IFN signature was 
associated with increased disease activity, as IFN gene 
scores were signiﬁ   cantly elevated in DM patients with 
active disease (n = 8) versus patients with inactive disease 
(n = 3).
Also in 2007, Greenberg and colleagues demonstrated 
an IFN-inducible gene expression signature in peripheral 
blood mononuclear cells of both DM patients (n = 12) 
and PM patients (n = 11) [24]. In fact, of the 25 genes 
most diﬀ  erentially expressed in patients with active DM, 
21 genes were known to be type I IFN inducible. In eight 
patients with follow-up samples available, levels of IFN-
inducible genes generally decreased as clinical disease 
activity improved. Th   is study suggested that the levels of 
IFN-inducible transcripts were highest in DM, but were 
also signiﬁ  cantly elevated in PM patients compared with 
healthy controls. In the muscle, however, the upregu-
lation of IFN signature genes was dramatically higher in 
DM versus PM; IFN signature transcript levels were 
similarly low in both PM and IBM. Th  is study also 
aﬀ  orded the unique opportunity to directly compare gene 
expression in matched blood samples and muscle 
biopsies obtained from ﬁ  ve DM patients. In a re-analysis 
of their previously published muscle microarray data, the 
authors found that, while IFN-inducible genes were 
generally upregulated in both blood and muscle, the 
degree of upregulation for some genes was much greater 
in the muscle samples than in blood. Th  is ﬁ  nding may 
reﬂ   ect more dramatic activation of the type I IFN 
pathway at sites of active inﬂ   ammation in the target 
tissue.
More recently, we used quantitative real-time RT-PCR 
to examine IFN signature gene expression in blood 
samples from a cohort of 56 DM patients (37 ADM and 
19 JDM) and 20 healthy controls [25]. As expected, IFN 
signature genes were signiﬁ   cantly upregulated in DM 
patient blood cells as compared with the healthy controls. 
We also found that the IFN gene signature was signiﬁ  -
cantly correlated with myositis disease activity as 
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(VAS). With respect to speciﬁ  c clinical manifestations of 
DM, the IFN gene score was signiﬁ  cantly correlated with 
constitutional, cutaneous, composite extraskeletal muscle, 
and muscle activity scores, as well as with the MMT8 
score (an assessment of muscle strength based on manual 
muscle strength testing of eight muscle groups). How-
ever, IFN gene scores did not correlate with other labora-
tory indicators of inﬂ  ammation, such as the erythro  cyte 
sedimentation rate or C-reactive protein. Th  is study 
represented the largest DM cohort to date demonstrating 
an association between the blood IFN signature and 
myositis disease activity.
Studies of type I IFN itself in autoimmune disease are 
hampered by technical diﬃ   culties of measuring type I 
IFN protein in the blood using standard immunoassays, 
which may include the presence of blocking antibodies in 
patient sera, nonspeciﬁ  c immunoreactivity, and the rela-
tively low concentration of some cytokines. As a result, 
most studies of the IFN signature in autoimmunity have 
relied upon measurement of IFN-inducible transcripts 
and proteins in lieu of measuring the type I IFNs them-
selves. In an attempt to demonstrate which members of 
the type I IFN family are most closely associated with the 
IFN gene signature in DM, Liao and colleagues measured 
serum levels of IFNα, IFNβ, and IFNω in 70 individuals 
(24 DM, 12 PM, 15 IBM, seven other myopathy, and 12 
normal controls) by ELISAs with detection limits of 
3.13 pg/ml for IFNα, 1.15 pg/ml for IFNβ and 2.40 pg/ml 
for IFNω [26]. In the same cohort, the authors measured 
IFN-inducible gene expression in blood cells. Th  ey 
further tested the ability of serum from these individuals 
to stimulate type I IFN-inducible gene expression signa-
tures in a functional assay, using an IFN-stimulated 
response element reporter cell line. In order to control 
for possible artifactual detection of IFNs, and the 
possibility that protein levels measured by ELISA might 
not reﬂ  ect biologic activity as measured by the reporter 
assays, the authors compared ELISA results with the 
bioassay results. IFNβ serum levels, but not IFNα or 
IFNω, were highly associated with DM. Furthermore, 
IFNβ levels were signiﬁ  cantly correlated with IFN gene 
signatures from matched blood samples. In contrast, 
IFNα and IFNω levels did not show evidence for 
correlation with IFN gene signatures. Measurement of 
other type I IFN family members could shed additional 
light on the most relevant cytokines to the IFN signature 
observed in DM patients.
Because of the potential diﬃ   culties  in  accurately 
measuring type I IFNs in blood, Niewold and colleagues 
used another functional reporter cell assay (measuring 
IFN-induced gene expression the WISH cell line) to 
detect type I IFN activity in blood samples from 39 JDM 
patients [27]. Samples were obtained at the time of 
diagnosis for 18 of the patients; for the remaining 21 
patients, samples were obtained 3 years after diagnosis. 
Blocking experiments performed in the reporter cell 
assay were used to elucidate the most probable IFN 
subtype. Th  e authors observed elevated serum IFNα 
activity in newly diagnosed, untreated JDM patients 
versus control subjects. Th  ey also found a signiﬁ  cant 
increase in serum IFNα activity in untreated patients 
versus treated patients. Serum IFNα activity correlated 
signiﬁ   cantly with several measures of disease activity 
(serum CK, AST, aldolase in untreated patients, aldolase 
and LDH in treated patients). However, IFNα activity 
increased over time to near untreated levels with unclear 
clinical correlation. Th  e authors also provided evidence 
that IFNα activity was associated with the DM risk allele 
TNFa-308A. Although the number of individuals in each 
TNFa-308A subcategory was relatively small, these data 
suggested that the TNFa-308 allele may play a role in 
predisposing individuals to increased type I IFN activity. 
A later study suggested that serum IFNα activity may be 
particularly high in DM patients who carry both the 
TNFa-308 risk allele and the minor allele at a second SNP 
in the osteopontin gene, which has been previously 
associated with serum cytokine proﬁ  les in systemic lupus 
erythematosus (SLE) [28]. However, because of the 
limited sample size (three to ﬁ   ve patients per group), 
replication in larger cohorts is required to conﬁ  rm this 
ﬁ  nding.
Given that the IFN signature is a prominent feature in 
other autoimmune diseases beyond DM, including SLE, 
Sjögren’s syndrome, and systemic sclerosis, a direct 
comparison of the IFN signature across diseases may be 
useful. Greenberg and colleagues qualitatively compared 
selected IFN signature genes between DM muscle and 
SLE blood samples, using four previously published SLE 
microarray studies [7,29-32]. Th  ey described 16 IFN-
inducible genes that were upregulated in DM muscle and 
were reported to be upregulated in SLE blood in at least 
one of the four published studies. In our microarray 
studies, we have directly compared the levels of IFN-
inducible gene expression between DM blood and SLE 
blood. We found that the degree of upregulation of IFN 
signature transcripts in blood cells is very similar 
between DM and SLE [23]. We also found that the 
speciﬁ   c subset of IFN-inducible genes that are 
upregulated in DM is very similar to the gene set that is 
upregulated in SLE blood cells (Figure 1) [23] (ECB, HB 
and AMR, unpublished data, 2010). Consistent with the 
idea that IFN pathway activation may be a shared patho-
genic factor among these diseases, Niewold and 
colleagues found that serum IFNα levels were higher in 
ﬁ  ve untreated JDM patients with a family history of SLE 
compared with 13 untreated patients without a family 
history of SLE [33].
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juvenile and adult dermatomyositis
Mechanisms leading to induction of type I IFN in DM are 
still largely unknown; however, there is increasing 
evidence pointing to a role for dendritic cells followed by 
Toll-like   receptor (TLR) induction. Type I IFNs are 
primarily secreted from pDCs with the type I IFNs 
inﬂ   uencing tissues such as myocytes in muscle and 
keratinocytes in skin. Th   e type I IFN secretion is thought 
to follow various triggers or cell stressors such as 
infection, MHC class I upregulation, the unfolded protein 
response or UV light exposure. All of these triggers or 
stressors could lead to maturation of dendritic cells, both 
pDCs and myeloid dendritic cells, and secretion of cyto-
kines and chemokines, especially those directly related to 
type I IFN secretion by the dendritic cells.
Kim and colleagues found evidence for increased TLR9 
expression in DM (n = 9) and PM (n = 5) muscle com-
pared with controls (n = 3), along with other TLRs and 
cytokines [34]. Signaling through the DNA-sensing TLR9 
leads to potent induction of type I IFN [35]. Although 
this study included relatively few subjects, it suggests that 
signaling through TLR9 may be contributing to the IFN 
signature observed in the muscle of patients with DM.
Cappelletti and colleagues also examined the relation-
ship between type I IFN and TLR induction, and suggest-
ed that TLR induction might be secondary to tissue 
damage [36]. Th  is study commented on diﬀ  erent  IFN 
induction pathways in myeloid dendritic cells via TLR3 
versus those in pDCs via TLR7 and TLR9. Th  e group 
discusses several factors that may lead to TLR3 
upregulation: possibly a direct response of the endo-
thelium to a viral pathogen; possibly produced secondary 
to muscle tissue remodeling; and possibly induced by 
oxidative stress caused by the ischemia/reperfusion 
charac  teristic of DM. Th   is group used microarray 
analysis to demonstrate that both endolysosomal TLRs 
(TLR3, TLR7, and TLR9) as well as type I IFN-inducible 
genes were upregulated in JDM and ADM muscle com-
pared with control muscle. Th   e most upregulated genes 
in this experiment were a viral response gene, 15 kDa 
IFN-stimulated ubiquitin-like modiﬁ  er protein (ISG15) 
and IFN-induced protein with tetratricopeptide repeats 3 
(IFIT3), known to be upregulated in IFN-mediated 
antiviral immunity. Th  ese  ﬁ  ndings suggest that the type I 
IFN pathway and TLRs are upregulated together, and 
again direct attention to a possible viral contribution to 
JDM and ADM.
Myositis-specifi  c antibodies and their role in 
genetic modulation
Another signiﬁ  cant component of disease pathogenicity 
in DM is the presence of autoantibodies that are common 
in other autoimmune diseases, including anti-SSA, 
anti-SSB, anti-Sm and myositis-speciﬁ  c  autoantibodies 
(MSAs). Th   e MSAs associate with speciﬁ  c  clinical 
manifestations of disease and target either nuclear or 
cytoplasmic components involved in antiviral responses 
and gene transcription. MSAs include autoantibodies 
directed against the aminoacyl tRNA-synthetase enzymes 
(including Jo-1, the most common MSA), Mi-2 protein, 
and novel MSAs such as anti-small ubiquitin-like 
modiﬁ   er activating enzyme, anti-p155/140, and anti-
p140 [37]. It is not clear whether these auto  antibodies are 
secondary to disease or directly linked to pathogenesis. 
Recently, there has been accumulating evidence for a 
proposed role of their autoantigen targets in myositis 
pathogenesis.
Th   e anti-aminoacyl tRNA-synthetase enzyme auto  anti-
bodies deﬁ   ne the anti-synthetase syndrome. Th  ese 
antibodies are observed in adult myositis (up to 40%) 
more often than in JDM (1 to 3%) [37]. Eloranta and 
colleagues showed that immune complexes containing 
either anti-Jo-1 or anti-Ro in the presence of RNA may 
act as endogenous inducers of type I IFNα in DM [38], 
suggesting a role for anti-Jo-1 autoantibodies in IFN 
production and disease patho  genesis. Anti-Mi-2 is 
detected frequently in JDM and ADM (up to 20% [39]). 
Mi-2, a nuclear helicase protein, forms part of the 
nucleosome-remodeling deacetylase complex that plays a 
role in gene transcription [40]. Th  is autoantibody is 
detected in patients with cutaneous DM lesions. Guna-
wardena and colleagues identiﬁ  ed a novel auto  antibody 
speciﬁ  c to adult DM (8.4% of adult DM are positive), 
anti-small ubiquitin-like modiﬁ   er activating enzyme, 
whose target is a protein involved in post-translational 
modiﬁ  cations and might associate with systemic features 
such as dysphagia [37]. Another novel MSA speciﬁ  c to 
adult DM is anti-p155/140, which was named based on 
the molecular weight of the polypeptide targets. Presence 
of this autoantibody was associated with cutaneous 
involvement and an increased risk of malignancy [41].
Anti-p155/140 autoantibodies were also reported in 
23% of JDM cases [37]. Th  e p155 target of this doublet 
polypeptide has been identiﬁ  ed as transcriptional inter-
mediary factor 1γ, a nuclear protein involved in cellular 
diﬀ   erentiation [42]. Distinct from anti-p155/140 auto-
anti  bodies, anti-p140 autoantibodies (anti-MJ) were also 
detected in JDM [43]. Th   e target of this autoantibody is a 
nuclear matrix protein (NXP-2) that is involved in 
nuclear transcription [44]. Anti-p140 was signiﬁ  cantly 
associated with the presence of calcinosis [45].
Th   e common theme among these autoantigens is that 
their targets either mediate gene transcription or take a 
role in post-translational modiﬁ  cation. Defects in either 
of these functions can cause production of self-antigens 
and might indicate a common pathogenic mechanism in 
both ADM and JDM.
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dermatomyositis blood: is this a useful biomarker 
of disease?
It is intriguing to note that, while evidence for the 
eﬀ  ects of type I IFN activity is obvious in JDM and 
ADM, detection of type I IFNs themselves has not been 
reliably demonstrated, especially in the peripheral blood 
cells or as they relate to clinical disease activity. Th  e 
cellular source of type I IFNs remains to be deﬁ  ned, 
with pDCs being a likely major contributor. When and 
to what extent the IFN production occurs, however, is 
still un  clear. In psoriasis, another type I IFN-associated 
condi  tion, early upregulation is suggested to occur with 
levels decreasing later in the disease. Th  is results in 
greatly increased expres  sion of genes induced by type I 
IFNs, such as the IFN regulatory factor genes, which 
persist long after expres  sion of type I IFNs themselves 
subsides.
Even if type I IFNs themselves have not been identiﬁ  ed 
in the blood in ADM and JDM, however, type I IFN-
induced chemokines and cytokines are elevated in the 
peripheral blood from ADM and JDM, and to a lesser 
extent in PM.
Upregulation of MxA mRNA expression is seen in 
JDM; and with the identiﬁ  cation of an IFN gene signa-
ture, a question arises of whether the type I IFN-inducible 
proteins in the blood may be biomarkers for DM disease 
and also disease activity. More extensive serum levels of 
several type I IFN-inducible proteins were measured with 
elevated levels of IP-10, I-TAC, MCP-1, and MCP-2 
found in patients with the greatest degree of disease 
activity. Further prospective collection of samples during 
times of disease activity and inactivity in JDM and ADM 
showed a strong association of the deﬁ  ned type I IFN-
inducible chemokine and cytokines and T-helper type 17 
pathway cytokines such as IL-6 [25]. Levels of the four 
type I IFN-regulated chemokines (I-TAC, IP-10, MCP-1, 
and MCP-2) were measured in the peripheral blood from 
56 patients with JDM and DM subjects. Levels were 
correlated with the physician’s global assessment of 
disease activity (global VAS score), manual muscle 
testing, myositis disease activity scale, and VAS for skin 
and organ involvement. Levels of individual chemokines 
were each strongly correlated with the global VAS score 
(P  =  0.0001 for each) (Table  2). An even stronger 
correlation (r = 0.61, P <0.0001) was observed between 
the type I IFN chemokine score (summation of normal-
ized levels of the four chemokines) and the global VAS 
score. Similar correlations between the global VAS score 
and the type I IFN chemokine score were observed when 
the adult and juvenile patient groups were evaluated 
separately (ADM: r = 0.690, P = 0.0001; JDM: r = 0.532, 
Figure 1. Type I interferon-inducible genes are similarly regulated in dermatomyositis and systemic lupus erythematosus blood. 
Expression profi  les of 191 interferon (IFN)-inducible genes (rows) in peripheral blood cells from dermatomyositis (DM) patients (n = 12) [23] and 
systemic lupus erythematosus (SLE) patients (n = 48) (columns). Expression levels are shown as log2 ratios relative to healthy controls (n = 15 
controls for DM subjects; n = 37 controls for SLE subjects). Right-hand panel: expression of the same set of genes in type I IFN-stimulated peripheral 
blood mononuclear cells from four normal donors [29]. Expression levels shown as log2 ratios relative to PBS-treated control samples. The color scale 
refl  ects expression fold-changes from +8 (yellow) to –8 (blue). Demographics for normal donors for DM subjects: 73% (11/15) female, 80% (12/15) 
Caucasian, mean age 40.4 ± 11.0 years. Demographics for normal donors for SLE subjects: 100% (37/37) female, 97.3% (36/37) Caucasian, mean 
age 45.7 ± 6.4 years. Demographics for DM subjects: 10 adult DM and two juvenile DM, 91% Caucasian, 73% female, average age 43 ± 26 years. 
Demographics for SLE subjects: 97.9% (47/48) female, 45.8% (22/48) Caucasian, 41.7% (20/48) African American, mean age 41.5 ± 9.8 years.
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Page 7 of 11P = 0.03). Interestingly, when correlations between the 
global VAS score and the type I IFN gene score were 
assessed, a signiﬁ  cant correlation was observed in the 
adult DM cohort only (P = 0.003). Th   e type I IFN gene 
score was strongly correlated with the type I IFN chemo-
kine score in the pooled ADM and JDM population 
(r  =  0.53,  P  =  0.0003). Furthermore, the type I IFN 
chemokine score was strongly correlated with muscle-
speciﬁ   c disease activity indicators (muscle VAS score: 
r = 0.47, P = 0.0006; MMT8 score: r = −0.44, P = 0.002). 
Th   e levels of MIP-1α, a type I IFN-inducible chemokine, 
were also elevated in DM sera, and this was correlated 
with DM disease activity measured by a global VAS score. 
Type I IFN-inducible genes and their gene products thus 
appear to be promising biomarkers for monitoring 
disease activity in ADM and JDM through analysis of 
peripheral blood cells or serum.
Conﬂ  icting data exist on type I IFN detection in the 
peripheral blood of JDM and ADM subjects. JDM is 
reported to have a higher serum IFNα activity or 
products that are IFNα inducible (IFN-induced protein 
with tetratricopeptide repeats 1, myxovirus resistance 1, 
and RNA-dependent protein kinase) in the peripheral 
blood than both pediatric and adult healthy control 
subjects [27]. Th   ese IFNα-induced proteins are higher in 
untreated patients than after initiating therapy. However, 
the IFN-induced proteins increase back toward untreated 
levels on and oﬀ   treatment after 36 months. Th  ese  IFNα-
induced proteins were not associated with disease 
activity but were weakly associated with elevation of 
serum muscle enzyme levels (P  <0.05) prior to the 
introduction of therapy.
In a recently published study in ADM and PM, direct 
measurement of soluble IFNα in subjects who prefer-
entially had anti-Jo-1 antibodies and a muscle magnetic 
resonance imaging performed was compared in subjects 
before onset of treatment and with less than or more 
than 20 mg prednisone. IFNα levels were higher in all 
patients with anti-Jo-1 antibodies (P = 0.05), but medica-
tions did not signiﬁ  cantly  aﬀ   ect IFNα levels. Also a 
negative correlation was found between IFNα and the 
intensity of the magnetic resonance imaging signal 
(P = 0.0095) [46].
Additional peripheral blood studies of IFN concentra-
tions (IFNα, IFNβ and IFNω) measured by ELISA in 
adults with inﬂ   ammatory myositis found in 26 DM 
subjects that IFNβ elevation was seen in 35% (9/26), com-
pared with 6% (3/48) of other inﬂ  ammatory myopathies 
(IBM + PM) and 6% (2/36) of healthy volunteers. Levels 
of IFNβ, but not of IFNα or IFNω, were highly correlated 
with type I IFN-inducible gene expression in a functional 
assay. Th  e highest IFNβ levels were in those subjects 
prior to treatment or with minimal treatment (predni-
sone dose ≤15 mg/day or treatment duration ≤7 days) 
[26].
Interferon signature in adult versus juvenile 
dermatomyositis
Early reports of our group of type I IFN-regulated gene 
expression elevation in DM blood did not suggest 
Table 2. Interferon-regulated chemokines and other cytokines in adult and juvenile dermatomyositis subgroups 
compared with controls
  Healthy controls  Adult DM subjects  Juvenile DM subjects 
    Median  Median    Median  
   ( n = 26) 95%  CI (n = 56) 95%  CI P value  (n = 35) 95%  CI P value
IFN gene scorea  6.5  4.2 to 13.0  16.7  8.6 to 29.9  0.006  18.8  10.3 to 52.0  0.001
   ( n = 20)  (n = 51)    (n = 32)  
IFN chemokine scoreb  3.9  2.8 to 4.5  19.1  10.2 to 27.8  <0.0001  19.2  12.9 to 36.8  <0.0001
 IP-10c  40.4  34.1 to 47.1  1066.9  240.2 to 1816.2  <0.0001  881.9  427.9 to 2328.7  <0.0001
  ITAC  29.0  22.6 to 39.6  202.6  101.0 to 376.0  <0.0001  190.8  112.3 to 593.2  <0.0001
  MCP-1  339.1  280.3 to 430.6  954.8  630.9 to 1293.6  <0.0001  850.3  749.2 to 1285.5  <0.0001
Other  chemokines  and  cytokines       
  MIP-1β  180.9  163.2 to 208.3  179.1  149.2 to 219.5  0.808  207.8  168.2 to 250  0.301
  MIG  15.7  12.0 to 18.7  100.0  60.57 to 143.6  <0.0001  80.1  44.7 to 128.2  <0.0001
  IL-6  1.1  1.2 to 1.5  3.4  2.5 to 5.6  <0.0001  5.3  3.2 to 9.5  <0.0001
  IL-8  15.0  11.8 to 19.2  8.4  6.0 to 3.0  0.002  8.2  6.5 to 13.4  0.003
  IL-10  2.3  1.6 to 5.4  1.7  1.1 to 2.8  0.082  3.2  1.3 to 6.7  0.903
  TNFα  4.8  4.5 to 5.3  4.3  3.1 to 5.2  0.184  6.7  5.1 to 7.5  0.022
Signifi  cant P values (Mann–Whitney test P ≤0.05 for comparison against controls) presented in bold. CI, confi  dence interval; DM, dermatomyositis; IFN, interferon; 
MCP, monocyte chemoattractant protein; MIP, macrophage infl  ammatory protein. aCalculated using mean expression values of IFIT1, G1P2, and IRF7 measured by 
quantitative real-time RT-PCR. bCalculated using the normalized mean of IP-10, I-TAC, and MCP-1 levels in serum. cProtein levels are expressed as pg/ml.
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Page 8 of 11signiﬁ    cant diﬀ  erences between ADM (n = 10) and JDM 
(n  =  2) [23]. More recent publications report over-
expression of type I IFN-regulated genes and chemokines 
in peripheral blood of DM patients [25]. Th  e IFN 
chemokine score correlated signiﬁ   cantly with disease 
activity (global VAS) in both adult (n = 37) and juvenile 
(n = 19) cohorts, whereas the IFN gene signature corre-
lation with the global VAS was signiﬁ  cant only in adult 
DM [25].
In our more recent ﬁ  ndings in an expanded cohort, IFN 
gene and chemokine scores in the blood are not signiﬁ  -
cantly diﬀ  erent between ADM (n = 46) and JDM (n = 29) 
(Figure 2) (ECB, HB and AMR, unpublished data, 2010). 
IFN gene scores are signiﬁ   cantly correlated with DM 
disease activity in adults but not in children. In contrast, 
IFN chemokine scores are signiﬁ  cantly correlated with 
global VAS scores and muscle VAS scores in both ADM 
and JDM (Table 3), conﬁ  rming our previous observations. 
IFN chemokine scores were signiﬁ  cantly diﬀ  erent between 
active and inactive disease in both adults (P = 0.05) and 
children (P = 0.003). However, IFN gene scores were not 
signiﬁ  cantly diﬀ  erent between active and inactive disease 
in either adult or juvenile patients. Th   ese results suggest 
that the IFN chemokine score may be a potential disease 
activity biomarker in both ADM and JDM. Additional 
studies are required for better under  standing of IFN-
related mechanisms in both ADM and JDM pathogenesis.
Conclusions
Th  e type I interferon pathway is involved in the patho-
genesis of DM and is seen upregulated in both muscle 
and skin tissue as well as in peripheral blood cells. Th  e 
upregulation of this pathway may be a more sensitive 
marker of disease activity in DM.
Figure 2. Interferon gene and chemokine score distributions in adult and juvenile dermatomyositis patients not signifi  cantly diff  erent. 
P values calculated by Mann–Whitney test. Middle line represents the median, horizontal lines represent the minimum and maximum values, and 
central box represents the values from the 25th to 75th percentile. DM, dermatomyositis; IFN, interferon.
Table 3. Correlation of interferon gene scores and interferon chemokine scores in adult and juvenile DM patients
  Interferon gene score  Interferon chemokine score
  Adult DM (n = 44)  Juvenile DM (n = 27)  Adult DM (n = 44)  Juvenile DM (n = 29)
  r  P value   r  P value   r  P value   r  P value
Global VAS score  0.599  <0.0001  0.319 0.105 0.622  <0.0001  0.504  0.005
Muscle VAS score  0.674  <0.0001  0.357 0.07 0.606  <0.0001  0.431  0.02
Interferon gene score correlates with dermatomyositis (DM) disease activity measures, global visual analogue scale (VAS) score (as measured by physician on 1 to 100 
scale) and muscle VAS score in adult DM patients. Interferon chemokine scores correlate with DM disease activity measures, global VAS score and muscle VAS score in 
adult and juvenile DM patients. r, Pearson correlation coeffi   cient. Signifi  cant correlations (P <0.05) presented in bold.
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